476 related articles for article (PubMed ID: 30867304)
1. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
2. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
3. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
4. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
[TBL] [Abstract][Full Text] [Related]
5. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
[TBL] [Abstract][Full Text] [Related]
7. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Wei Q; Qin C; He Y
PLoS Pathog; 2019 Feb; 15(2):e1007552. PubMed ID: 30716118
[TBL] [Abstract][Full Text] [Related]
9. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
10. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
11. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
[TBL] [Abstract][Full Text] [Related]
12. Development of potent and long-acting HIV-1 fusion inhibitors.
Chong H; Wu X; Su Y; He Y
AIDS; 2016 May; 30(8):1187-96. PubMed ID: 26919736
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor.
Hu Y; Yu W; Geng X; Zhu Y; Chong H; He Y
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743078
[TBL] [Abstract][Full Text] [Related]
14. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
15. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y
Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
17. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.
Chen Y; Jin H; Tang X; Li L; Geng X; Zhu Y; Chong H; He Y
Emerg Microbes Infect; 2022 Dec; 11(1):30-49. PubMed ID: 34821542
[TBL] [Abstract][Full Text] [Related]
18. Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19.
He L; Wang C; Zhang Y; Chong H; Hu X; Li D; Xing H; He Y; Shao Y; Hong K; Ma L
Front Immunol; 2023; 14():1199938. PubMed ID: 37256122
[TBL] [Abstract][Full Text] [Related]
19. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
20. Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1.
Ikeda T; Tennyson RL; Walker SN; Harris RS; McNaughton BR
ACS Infect Dis; 2019 Apr; 5(4):634-640. PubMed ID: 30811933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
